Healthcare  Contact Us


There are many challenges facing healthcare, from aging populations, rapidly growing demand for health products and services, severe budget pressures and government reform to global health threats that defy conventional approaches. And each challenge requires the most imaginative of minds – people willing to ask big questions, take risks and tackle complex problems in new ways. At FleishmanHillard, we believe...

There are many challenges facing healthcare, from aging populations, rapidly growing demand for health products and services, severe budget pressures and government reform to global health threats that defy conventional approaches. And each challenge requires the most imaginative of minds – people willing to ask big questions, take risks and tackle complex problems in new ways. At FleishmanHillard, we believe there's an answer to every question that can be posed – we just have to be curious, persistent, collaborative and creative enough to find it. So regardless of the task – building brand loyalty, educating the public or defending a marketplace in the face of intense competition – our team provides the curiosity, experience and confidence to push the boundaries of healthcare communications.

What We Do

Reputation Management

Our teams provide a wide spectrum of reputation management consulting services, from support for leadership changes and mergers and acquisitions to employee communications, issues preparedness and crisis response. Equipped with proprietary tools such as our Authenticity Gap methodology, we help organizations across the healthcare sector identify and take positive steps toward managing the gaps between their brand and reputation.

Product Launch and Marketing

Each market and therapeutic category provides its own challenges, opportunities and circle of stakeholders. From clinical trial recruitment to end-of-lifecycle strategies, FleishmanHillard provides insights into the introduction and marketing of new and mature products. With a deep understanding of the regulatory environments and market complexities in which they work, our counselors have helped create powerful campaigns to launch products at a global, regional and national level – shaping a positive environment for product uptake and generating ongoing demand.

Clinical Trial Recruitment

FleishmanHillard provides specialized patient recruitment consulting for investigational pharmaceutical, biotechnology and medical device products. Working collaboratively with contract research organizations and our clients, we engage target populations through credible third-party sources – online and off – helping study sites raise awareness, educate and generate referrals.

Public Affairs and Government Relations

FleishmanHillard provides an in-depth understanding of local, regional and global healthcare issues, advocacy, alliance development, stakeholder engagement and government affairs. We help healthcare companies, trade associations and nongovernmental organizations navigate regulation, mobilize opinion leaders, and influence legislation and health policy. Our healthcare-focused public affairs experts around the world have extensive experience counseling organizations on the wide range of product, corporate and marketplace issues.

Digital and Social Outreach

FleishmanHillard’s digital and social experts worldwide help organizations apply new technologies, tools and channels to shape integrated communications programs that create a measurable impact. We work with clients to optimize the power of social media, including implementing policies for employees, launching branded promotional and unbranded educational campaigns, working with HR to enhance recruitment and retention, and coaching executives in the medium.


Animal healthcare
Health NGOs
Healthcare technology providers
Managed care and insurance providers
Medical equipment and device makers
Medical facilities and providers

Who We Are

  • Selling TrumpCare: Be Careful What You Promise

    Richard Sorian

    March 9, 2017

    Richard Sorian Having finally rolled out its legislative proposal to repeal and replace the Affordable Care Act, President Trump and the Republican leaders in Congress are scrambling to corral enough support to get the American Health Care Act (AHCA) through both houses of Congress with little or no Democratic support. Needing every vote they can get, the...

  • New Year, New Administration, New FDA and New Cures: Approvals and Enforcement Outlook for 2017

    Mark Senak

    January 11, 2017

    Mark Senak Every U.S. federal agency is facing the potential for considerable change given a new Administration taking office this month, setting into motion the process whereby new heads of bureaucracies assume responsibility and bring different priorities and agendas to their respective roles. But one – the Food and Drug Administration – which regulates one-fifth of the...

  • Four Reasons Why Obamacare Won’t Be Repealed In Trump’s First 100 Days

    Richard Sorian

    January 6, 2017

    Richard Sorian How Will Healthcare Fare in Trump’s First 100 Days? Ever since Franklin Roosevelt succeeded Herbert Hoover in the White House, the nation has focused tremendous attention on a new president’s first 100 days. As Donald J. Trump prepares to take office, national attention will turn again to the first 100 days to see how the...

  • These are Three Storylines We’re Watching at the J.P. Morgan Healthcare Conference

    Adam Silverstein

    January 5, 2017

    Adam Silverstein It’s that time of year again. We’re days away from the annual J.P. Morgan Healthcare Conference in San Francisco. All eyes will be on this gathering of the world’s biotechnology start-ups, pharmaceutical companies, medical device manufacturers, and health insurers. And it means that what company leaders say and the stories they tell media and investors,...

  • What's Next for 21st Century Cures Act?

    Mark Senak

    December 8, 2016

    Mark Senak The 21st Century Cures Act has been long in the making. First passed by the House of Representatives as in July 2015 by an overwhelming vote of 344 – 77, the bill hit the legislative wall in the Senate where, despite rumors of advancement over many months, it stayed put until after the election. Then,...

  • The Coming Battle Over Medicaid

    Richard Sorian

    November 17, 2016

    Richard Sorian President-elect Trump’s promise to convert the Medicaid program into a state-run block grant has tremendous implications for low-income and disabled Americans and their families. It can also have significant impact on key parts of the healthcare industry including the insurance, hospital, pharmaceutical and nursing home sector as well as physicians, dentists, and home health agencies....

  • President-Elect Trump & Healthcare

    Richard Sorian

    November 10, 2016

    Richard Sorian So the election-with-no-end is finally over and the nation is starting to sort out what the results will mean for a wide range of concerns including healthcare. While the candidates staked out very different positions, they spent very little time detailing their plans for healthcare. Now, President-elect Trump has begun the process of filling in...

  • Let’s Play Fantasy Baseball, Cabinet Version

    Richard Sorian

    September 6, 2016

    Richard Sorian I have never quite understood the allure of fantasy sports. Picking players from different teams based on past performance and your hunch of how they might play in the future on a team you create seems boring to me. As a kid, I do remember arguing with my older brother about whose baseball team was...

  • The Best of Cannes Lions Health: Smart Ideas, Well-Executed

    Heather Pierce

    June 20, 2016

    Heather Pierce The sheer volume of inspiring and excellent work shared at this year’s Cannes Lions Health has been remarkable—from breathtakingly beautiful films to stunning works of art and fantastically creative social campaigns. As I watched the awards ceremony presentations, I had two realizations. First, as health communicators we often get weighed down by our largely conservative...

  • Cannes Lions Health: Empathy Is the Key to Life-Changing Creativity

    Heather Pierce

    June 18, 2016

    Heather Pierce Earlier today at Cannes Lions Health, Genentech (a FleishmanHillard client) shared the powerful findings of their Lung Cancer Project, a study which sought to identify and understand unconscious bias. They found that an astonishing three out of four people had negative perceptions about lung cancer, which likely contributes to the high percentage of people diagnosed...

  • Why Media Coverage of Medical Research is Making John Oliver Mad, and What PR Pros Could Do to Help

    Adam Silverstein

    May 10, 2016

    Adam Silverstein You’ve seen the headlines. They appeared on your Facebook feed, your Twitter handle and your local news. You probably overheard someone mention one on your way to work. Maybe you’ve even seen these: “Swaddling May Be Linked to SIDS, New Research Analysis Suggests” “Eating Moderate Amounts of Chocolate Could Benefit Mom and Baby” “Drinking a...

  • Donald Trump’s 7-Point Healthcare Plan

    Richard Sorian

    March 4, 2016

    Richard Sorian Now that his road to the Republican nomination for President seems to be getting shorter, Donald Trump has released a seven-point plan for healthcare reform. But, like much in this campaign to date, it is short on details and new ideas. In fact, what’s remarkable about the plan is what is NOT in it. Trump’s...

  • Is It Enough to Mean Well? The Importance of Empathy

    Heather Pierce

    March 3, 2016

    Heather Pierce A few weeks ago, I was helping to lead a client message training session for an amazing group of female philanthropists. These women are leading incredible global health initiatives, from addressing gender-based violence in Honduras and Trinidad to transforming sanitation in Vietnam and detecting and treating cervical cancer in India. As we were discussing their...

  • Considerations for a New FDA Commissioner

    Mark Senak

    February 26, 2016

    Mark Senak The Senate, in an 89-4 vote, confirmed Dr. Robert Califf as the new Commissioner for the Food and Drug Administration, which oversees the regulation of about one-fourth of the U.S. economy. With several “Holds” put on the nomination by more than a few members, including Senators Manchin, Markey, Murkowski and Sanders the question was whether...

  • 10 Things We Know About the U.S. Presidential Candidates and Healthcare

    Richard Sorian

    February 24, 2016

    Richard Sorian The 2016 presidential election keeps rolling along with fewer candidates and many more primaries and caucuses. While issues like immigration and economic justice have dominated the debates and media coverage so far, healthcare continues to pop up fairly frequently. For example: Four candidates – Hillary Clinton, Bernie Sanders, Marco Rubio and Donald Trump – have...

  • Why Do Democrats Keep Fighting Over Healthcare?

    Richard Sorian

    February 2, 2016

    Richard Sorian “In short [my opponent] offers a flawed trillion-dollar plan that will cost the American people even more in the long run." "[My opponent] abandoned that fundamental Democratic principle of basic health care for all Americans.” You may think these quotes were quite likely uttered just last week as the Democrats running for President made their...

  • What a Difference a Year Makes: Three Observations from the JPM Healthcare Conference

    Adam Silverstein

    January 25, 2016

    Adam Silverstein Hotel room rates in San Francisco have resumed being just expensive, not uber-expensive. Union Square is crowded, not overflowing. Sports talk in bars and restaurants is more likely to be about real football – the Super Bowl, Monday morning quarterbacks, watching from the sidelines, dropping the ball – than borrowed football metaphors to describe business...

  • Keeping Score: The State of Healthcare in Obamaland

    Richard Sorian

    January 13, 2016

    Richard Sorian One of Washington’s favorite parlor games is to dissect major speeches by the President to see what signals he might be sending to the American people. How long was the speech? What topics got the most attention? The least attention? Did he mention my pet topic? The annual State of the Union (SOTU) address to...

  • Five Things to Watch for at the J.P. Morgan Healthcare Conference

    Adam Silverstein

    January 12, 2016

    Adam Silverstein San Francisco’s population is swelling, but the rising wave of people, much like the bay at high tide, will ebb. The flow of people into the city, specifically Union Square, is an effect of the 34th Annual J.P. Morgan (JPM) Healthcare Conference (JPM is a FleishmanHillard client), happening this week in San Francisco as it...

  • The Coming Storm

    Richard Sorian

    November 6, 2015

    Richard Sorian A sizzling summer of media coverage of rising drug prices – fueled by the made-for-TV news about Turing Pharmaceuticals’ 5000% price hike for Daraprim, a drug approved by the FDA in 1953 to treat malaria and toxoplasmosis – is turning into an autumn of activity on Capitol Hill. As a result, the long-brewing debate over...

  • What Really Scares Me This Halloween

    Fran Carpentier

    October 30, 2015

    Fran Carpentier Halloween’s calling, and my heart’s in the right place—for a person living with Type 1 diabetes, that is. You see, despite my compliance to carb-counting and almost hourly blood tests, I’ve deep-rooted affection for this holiday of camp and kitsch and candy. But just like Cinderella (my all-time favorite princess-in-waiting if not Halloween costume), I...

  • A Healthy Debate – What the Candidates Are Saying

    Richard Sorian

    October 15, 2015

    Richard Sorian U.S. presidential candidates from both parties have now held at least one nationally televised debate and healthcare played a prominent role in both. We ran a quick analysis of the most current Republican and Democratic debate transcripts, and some of what was said really surprised us. Think you know what’s what? Try this fast quiz:...

  • Can Technology Bridge the Gap Between Knowing and Doing?

    Heather Pierce

    October 14, 2015

    Heather Pierce Chronic disease prevention isn’t sexy. Its core tenets induce eye rolls with their basic simplicity: “Eat better. Exercise more.” Ugh, how boring. Isn’t there some pill I can take to stave off a heart attack or cancer? A one-time shot to make me diabetes-proof? Healthcare providers and public health professionals have long struggled with how...

  • Speaking of Health – How the 21st Century Cures Act Impacts Healthcare Communications

    Mark Senak

    July 10, 2015

    Mark Senak The pace of change in healthcare is breathtaking. There are new ways to treat, new ways to research, new ways to pay for care, new ways to access care and new ways to communicate about it. Yet, in too many ways, the way we, as a nation, regulate remains a 20th century model plagued by...

  • SCOTUS Saves POTUS: How the ACA Verdict Affects Healthcare

    Richard Sorian

    June 25, 2015

    Richard Sorian Today’s 6-3 decision by the Supreme Court of the United States (SCOTUS) hands a huge victory to Barack Obama, the President of the United States (POTUS), locking in place one of the President’s signature public policy initiatives of his two terms in the White House. While the political debate and legal challenges to the Affordable...

  • Social Media at ASCO: Weekend in Review

    Adam Silverstein

    June 1, 2015

    Adam Silverstein Day 4 at the American Society of Clinical Oncology (ASCO) conference in Chicago brings with it some weary attendees and followers. Hundreds of abstracts have been presented on a range of cancers and generated some large conversation volumes, both in McCormick Place and online. On Friday, we previewed three topics and trends we’re watching at the meeting....

  • Sweet Home Chicago: What We’ll Be Watching at ASCO

    Adam Silverstein

    May 29, 2015

    Adam Silverstein Chicago, get ready. You’re about to have a lot more doctors, business executives and journalists. Thousands of them are gathering in the Windy City for the annual American Society of Clinical Oncology (ASCO), one of the largest oncology meetings in the world. While the surge will be temporary, the research and insights shared by oncologists...

  • Are We Too Optimistic About Progress in Cancer?

    Adam Silverstein

    April 29, 2015

    Adam Silverstein A giddy smile has taken hold of the faces of many oncologists and cancer patients. They have good reason to grin, for three reasons: We could be on the way toward doing away with the cancer biopsy. Researchers reported that a “liquid biopsy” blood test that’s possible due to advanced genome sequencing can find tiny pieces of cancer DNA in...

  • The FH 2015 Social Health Survey: A Second Opinion From Dr. Digital

    Alyssa Marderstein

    April 20, 2015

    Alyssa Marderstein Melissa Solomon and Adam Silverstein contributed to this article. Survey finds over 50% of patients consult with Dr. Google or Facebook before or after a doctor’s visit Our Social Health survey of more than 500 people reveals some important patient behaviors. First, patients form an opinion about a treatment option before they step foot in...

  • The FleishmanHillard 2015 Social Health Survey

    Ephraim Cohen

    April 7, 2015

    How people care for themselves and others using social and mobile media Which networks people use and how they use them differs greatly depending on age range as well as whether the person is looking for information about their own health or finding information as a caregiver to someone else. The charts below show the...

Most Recent

  • Selling TrumpCare: Be Careful What You Promise

  • New Year, New Administration, New FDA and New Cures: Approvals and Enforcement Outlook for 2017

  • Four Reasons Why Obamacare Won’t Be Repealed In Trump’s First 100 Days

  • These are Three Storylines We’re Watching at the J.P. Morgan Healthcare Conference

  • What's Next for 21st Century Cures Act?

By Author

By Date